In a patient w/ IgG Lambda standard risk MM who is not a suitable transplant candidate due to cardiac status and has maintained VGPR on Dara-Revlimid for the past 2 years (not currently on steroids due to issues with volume overload from heart failure), when do you consider de-escalating treatment? Or would you continue DR until no longer able to tolerate?
Data from the MAIA trial supports continuing Dara-rev until progression or intolerance. One option if you haven't already done is reduce the rev from 25mg to 10mg.
